DAS-431 IV is a dopamine D1 receptor agonist developed by DrugAbuse Sciences for the treatment of Addictions, Schizophrenia, Schizoaffective Disorders, Dementia, Parkinson's Disease, Strokes etc.
- Mechanism
- Curator reviewed
DAS-431 IV is a dopamine D1 receptor agonist which is in Phase II evaluation for the treatment of cognitive impairment in the elderly and cocaine addiction and is in development for a broad range of CNS diseases, including schizophrenia. Dopamine D1 receptors are thought to play a role in mediating cognitive processes in the prefrontal cortex, particularly working memory. The number of D1 receptors appears to be decreased in the elderly, chronic addicts, patients with schizophrenia and, possibly, patients with Parkinson's disease and those who have experienced a stroke. DAS-431 directly activates D1 receptors in the prefrontal cortex and may be useful in treating these conditions.
- Primary indication
- Investigated for use/treatment in addictions, dementia, parkinson's disease, schizophrenia and schizoaffective disorders, and strokes.Curator reviewed
- Code names
- DAS-431 IV
Resolves to
What you can answer from here — as of April 02, 2025
Which drugs share a target with DAS-431 IV, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account